سعر سيروكسات 12.5مجم 30 قرص 2024

Paroxetine 12.5 mg controlled-release film-coated oral tablets (Seroxat CR, GSK), pack of 30; SSRI antidepressant.

• Most common (>=5% and at least twice placebo): abnormal ejaculation, abnormal vision, asthenia, constipation, decreased appetite, diarrhoea, dizziness, dry mouth, female genital disorder, impotence, insomnia, decreased libido, nausea, somnolence, sweating and tremor.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Use with, or within 14 days of stopping, MAOIs (including linezolid and intravenous methylene blue).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Concomitant drugs that prolong the QTc interval and are CYP2D6 substrates.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to paroxetine or any inactive ingredient (anaphylaxis, angioedema and Stevens-Johnson syndrome reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: antidepressants increased the risk of suicidal thoughts and behaviours in pediatric and young adult patients; monitor all patients for clinical worsening and emergent suicidality.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Other warnings: serotonin syndrome, embryofetal toxicity, increased bleeding risk (monitor INR with warfarin), activation of mania/hypomania, discontinuation syndrome, seizures, angle-closure glaucoma, hyponatraemia and sexual dysfunction.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• MAOIs (including linezolid, IV methylene blue)Contraindicated: risk of serotonin syndrome; allow at least 14 days between stopping one and starting the other.DailyMed (U.S. National Library of Medicine)
• Warfarin and other drugs affecting haemostasis (NSAIDs, aspirin)Increased bleeding risk; monitor INR when starting, titrating or stopping paroxetine in patients on warfarin.DailyMed (U.S. National Library of Medicine)
• QTc-prolonging CYP2D6 substrates (e.g., thioridazine, pimozide)Contraindicated: paroxetine is a strong CYP2D6 inhibitor and raises their levels.DailyMed (U.S. National Library of Medicine)

• For women who intend to become pregnant or are in the first trimester, start paroxetine only after considering other treatment options. Late-pregnancy SSRI exposure carries risks of persistent pulmonary hypertension of the newborn and poor neonatal adaptation, and exposure in the month before delivery is associated with a less than 2-fold increase in postpartum haemorrhage.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Paroxetine is present in human milk (relative infant dose about 0.4-2.2%); agitation, irritability, poor feeding and poor weight gain have been reported in exposed infants, who should be monitored.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.